cabotegravir
LA-ART Suppresses HIV in Underserved Populations
Comprehensive support services combined with a long-acting antiretroviral treatment given every four to eight weeks ...
FEBRUARY 21, 2023
FDA Approves Cabenuva Long-Acting HIV Treatment
cabotegravir plus rilpivirine is dosed once monthly as an option to replace a patient’s current ...
JANUARY 22, 2021
FDA Declines Approval for Cabotegravir-Rilpivirine Long-Acting Combo for HIV
The long-acting injectable received a complete response letter due to chemistry manufacturing and controls. Viiv ...
DECEMBER 23, 2019
Load more